This methodology will therefore offer a crucial solution to drug manufacturers to track and control N-nitroso leucovorin and Di-nitroso leucovorin concentrations, which will have a positive impact on regulatory compliance and patient safety.
Yalamanchili et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: